Oragenics, Inc.

Oragenics, Inc. is a development-stage biotechnology company dedicated to developing drugs and therapies focused on the nasal delivery of pharmaceutical medications in neurology. Leveraging cutting-edge intranasal technology and powdered drug formulations, the company aims to address critical unmet medical needs, with a primary focus on concussions. Its mission is to pioneer neurological health solutions that offer tangible improvements for millions of patients, moving beyond mere symptom management. The company's headquarters are located in Sarasota, Florida.

The company's lead product candidate is ONP-002, a first-in-class neurosteroid delivered via a proprietary intranasal system designed for rapid brain absorption. ONP-002 is currently in development for the treatment of mild traumatic brain injury (mTBI), commonly known as concussion. Beyond concussion, Oragenics' proprietary intranasal delivery platform holds potential for broader applications across various neurological conditions, including neurodegenerative diseases and central nervous system disorders. The company pivoted its focus to neurology in January 2024, following the acquisition of neurological assets from Odyssey Health, Inc., having previously engaged in antibiotic research and vaccine development.

In recent developments, Oragenics reported dosing patients in its Phase IIa clinical trial of ONP-002 for mild traumatic brain injury in April 2026, following Human Research Ethics Committee (HREC) approval in Australia in March 2026. Janet Huffman serves as the Chief Executive Officer and Chief Financial Officer. The company is strategically positioning itself to address the significant unmet medical needs in the neurological market, with the global concussion treatment market projected to reach $8.9 billion by 2027.